HIV and HAART-Associated Dyslipidemia

Eoin R Feeney1, *, Patrick W.G Mallon 1, 2
1 HIV Molecular Research Group, School of Medicine and Medical Science, University College Dublin, Dublin, Ireland
2 Department of Infectious Diseases, Mater Misericordiae University Hospital, Dublin, Ireland

Article Metrics

CrossRef Citations:
Total Statistics:

Full-Text HTML Views: 1881
Abstract HTML Views: 1814
PDF Downloads: 994
Total Views/Downloads: 4689
Unique Statistics:

Full-Text HTML Views: 834
Abstract HTML Views: 985
PDF Downloads: 719
Total Views/Downloads: 2538

Creative Commons License
© Feeney and Mallon; Licensee Bentham Open.

open-access license: This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.

* Address correspondence to this author at the School of Medicine and Medical Science, University College Dublin, Dublin 2, Ireland; Tel: +353 1 7166518; Fax: +353 1 7166335; E-mail:


Effective highly active antiretroviral therapy (HAART) for human immunodeficiency virus-1 (HIV) infection has led to marked improvement in life-expectancy for those infected with HIV. Despite reductions in the incidence of AIDS with effective treatment, patients continue to experience considerable morbidity and mortality from non-AIDS illness such as premature cardiovascular disease, liver failure and renal failure. These morbidities, particularly premature cardiovascular disease, are thought to be related to a combination of the effects of an ageing HIV-infected population coupled with long-term effects of HIV infection and antiretroviral therapy (ART). One of the principle drivers behind the well documented increase in the risk of cardiovascular disease in HIV-infected patients is dyslipidemia.

This review will focus on the clinical presentation of HIV and ART-associated dyslipidemia, what is known of its patho-physiology, including associations with use of specific antiretroviral medications, and suggest screening and management strategies.

Keywords: HIV, HAART, dyslipidemia, cholesterol, triglycerides, lipids..